English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04109066 /

CA209-7FL

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study Of Nivolumabversus Placebo In Combination With Neoadjuvant Chemotherapy And Adjuvant Endocrine Therapy In Patients With High-Risk, Estrogen Receptor-Positive (ER+), Human Epidermalgrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

DISEASE GROUP:
Breast Cancer Clinical Trials
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: